
Charles River Laboratories International CRL
$ 183.47
3.69%
Annual report 2025
added 02-18-2026
Charles River Laboratories International Operating Cash Flow 2011-2026 | CRL
Annual Operating Cash Flow Charles River Laboratories International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 738 M | 735 M | 684 M | 620 M | 761 M | 547 M | 481 M | 441 M | 318 M | 317 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 761 M | 317 M | 564 M |
Quarterly Operating Cash Flow Charles River Laboratories International
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 172 M | - | - | - | 130 M | - | - | - | 109 M | - | 385 M | - | 103 M | - | 532 M | - | 170 M | - | 408 M | 231 M | 68.6 M | - | 300 M | 144 M | 14.9 M | - | - | 184 M | 60.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 532 M | 14.9 M | 201 M |
Operating Cash Flow of other stocks in the Diagnostics research industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-21.7 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
1.48 B | $ 121.25 | 2.54 % | $ 36.9 B | ||
|
Burning Rock Biotech Limited
BNR
|
-478 M | $ 21.33 | -5.2 % | $ 230 M | ||
|
Accelerate Diagnostics
AXDX
|
-48.7 M | - | -61.36 % | $ 2.46 M | ||
|
Aspira Women's Health
AWH
|
-7.03 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
-13.3 M | - | -13.05 % | $ 7.29 M | ||
|
Check-Cap Ltd.
CHEK
|
-8 M | - | - | $ 9.42 M | ||
|
Chembio Diagnostics
CEMI
|
-12.7 M | - | 0.22 % | $ 16.8 M | ||
|
CareDx, Inc
CDNA
|
42 M | $ 22.09 | -1.47 % | $ 1.18 B | ||
|
DermTech
DMTK
|
-77 M | - | -11.32 % | $ 2.94 M | ||
|
Akumin
AKU
|
65.4 M | - | -17.87 % | $ 25.9 M | ||
|
Enzo Biochem
ENZ
|
-26.3 M | - | -8.98 % | $ 14.8 K | ||
|
Co-Diagnostics
CODX
|
-29.1 M | $ 1.52 | 4.12 % | $ 2.02 M | ||
|
Exact Sciences Corporation
EXAS
|
491 M | - | - | $ 19.8 B | ||
|
Castle Biosciences
CSTL
|
64.9 M | $ 25.08 | 2.13 % | $ 697 M | ||
|
Global Cord Blood Corporation
CO
|
614 M | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
-5.66 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-524 M | - | 0.12 % | $ 80.1 M | ||
|
Danaher Corporation
DHR
|
6.42 B | $ 195.86 | 1.07 % | $ 140 B | ||
|
Interpace Biosciences
IDXG
|
5.83 M | $ 2.0 | -9.09 % | $ 8.85 M | ||
|
Heska Corporation
HSKA
|
-21.8 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-18.4 M | - | -20.0 % | $ 1.06 M | ||
|
Medpace Holdings
MEDP
|
713 M | $ 519.83 | 0.81 % | $ 15 B | ||
|
Illumina
ILMN
|
837 M | $ 134.35 | 1.23 % | $ 21.4 B | ||
|
Myriad Genetics
MYGN
|
1.8 M | $ 5.19 | 3.7 % | $ 481 M | ||
|
NeoGenomics
NEO
|
5.23 M | $ 8.38 | 2.63 % | $ 1.07 B | ||
|
Neogen Corporation
NEOG
|
58.2 M | $ 9.64 | 4.33 % | $ 2.09 B | ||
|
Fulgent Genetics
FLGT
|
21.1 M | $ 16.34 | 1.3 % | $ 494 M | ||
|
Precipio
PRPO
|
685 K | $ 28.81 | -0.66 % | $ 46.2 M | ||
|
Guardant Health
GH
|
-185 M | $ 90.83 | 5.99 % | $ 11.4 B | ||
|
QIAGEN N.V.
QGEN
|
654 M | - | - | $ 10.6 B | ||
|
Anixa Biosciences
ANIX
|
-7.17 M | $ 2.83 | - | $ 91.8 K | ||
|
Biomerica
BMRA
|
-3.84 M | $ 2.18 | -0.91 % | $ 5.01 M | ||
|
Motus GI Holdings
MOTS
|
-11.2 M | - | -34.28 % | $ 263 K | ||
|
ICON Public Limited Company
ICLR
|
1.29 B | $ 119.42 | 3.32 % | $ 9.85 B | ||
|
Laboratory Corporation of America Holdings
LH
|
1.64 B | $ 273.05 | 2.51 % | $ 22.7 B | ||
|
Senseonics Holdings
SENS
|
-59.1 M | $ 6.8 | 0.44 % | $ 284 M | ||
|
Celcuity
CELC
|
-153 M | $ 123.43 | -1.45 % | $ 5.77 B | ||
|
Soleno Therapeutics
SLNO
|
46.8 M | $ 52.67 | 0.18 % | $ 2.68 B | ||
|
Lantheus Holdings
LNTH
|
390 M | $ 84.14 | 0.26 % | $ 5.68 B | ||
|
Neuronetics
STIM
|
-20.4 M | $ 1.44 | 2.86 % | $ 95 M | ||
|
Quest Diagnostics Incorporated
DGX
|
1.89 B | $ 195.61 | 2.17 % | $ 21.7 B | ||
|
ENDRA Life Sciences
NDRA
|
-5.18 M | $ 6.01 | 16.27 % | $ 4.73 M | ||
|
Thermo Fisher Scientific
TMO
|
7.82 B | $ 526.97 | 2.13 % | $ 199 B | ||
|
Trinity Biotech plc
TRIB
|
13.2 M | $ 0.68 | -2.63 % | $ 61.9 M |